Trial · NCT03779113
Adverse events1,652
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,652
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pyrexia | General disorders | Dose Escalation Stage: HMPL-523 100 mg QD | 0 | 4 | 0 |
| other | Pyrexia | General disorders | Dose Escalation Stage: HMPL-523 200 mg QD | 0 | 3 | 0 |
| other | Pyrexia | General disorders | Dose Escalation Stage: HMPL-523 400 mg QD | 1 | 3 | 1 |
| other | Pyrexia | General disorders | Dose Escalation Stage: HMPL-523 600 mg QD | 2 | 3 | 2 |
| other | Pyrexia | General disorders | Dose Escalation Stage: HMPL-523 700 mg QD | 0 | 4 | 0 |
| other | Pyrexia | General disorders | Dose Escalation Stage: HMPL-523 800 mg QD | 2 | 4 | 2 |
| other | Pyrexia | General disorders | Dose Expansion Stage: HL | 4 | 25 | 6 |
| other | Pyrexia | General disorders | Dose Expansion Stage: CLL | 0 | 1 | 0 |
| other | Pyrexia | General disorders | Dose Expansion Stage: CLL-post BTK | 3 | 7 | 4 |
| other | Pyrexia | General disorders | Dose Expansion Stage: FL | 0 | 2 | 0 |
| other | Pyrexia | General disorders | Dose Expansion Stage: MZL | 0 | 1 | 0 |
| other | Pyrexia | General disorders | Dose Expansion Stage: LPL/WM | 0 | 1 | 0 |
| other | Pyrexia | General disorders | Dose Expansion Stage: MCL | 1 | 2 | 1 |
| other | Pyrexia | General disorders | Dose Expansion Stage: PTCL | 1 | 9 | 1 |
| other | Asthenia | General disorders | Dose Escalation Stage: HMPL-523 100 mg QD | 0 | 4 | 0 |
| other | Asthenia | General disorders | Dose Escalation Stage: HMPL-523 200 mg QD | 0 | 3 | 0 |
| other | Asthenia | General disorders | Dose Escalation Stage: HMPL-523 400 mg QD | 1 | 3 | 1 |
| other | Asthenia | General disorders | Dose Escalation Stage: HMPL-523 600 mg QD | 1 | 3 | 2 |
| other | Asthenia | General disorders | Dose Escalation Stage: HMPL-523 700 mg QD | 1 | 4 | 1 |
| other | Asthenia | General disorders | Dose Escalation Stage: HMPL-523 800 mg QD | 1 | 4 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03779113/events